Fresh Tracks Therapeutics, Inc.
FRTXNASDAQHealthcare
$0.94
$-0.01(-0.53%)
Market Cap$5585045
P/E Ratio—
52W High$1.0325
52W Low$0.03
Fresh Tracks Therapeutics, Inc. (FRTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FRTX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $8.01M | $6.94M | $0.40M | $1.82M | $7.92M |
| Cost of Revenue | $0.00M | $14.04M | $28.23M | $11.22M | $20.21M |
| Gross Profit | $8.01M | ($7.10M) | ($27.83M) | ($9.39M) | ($12.30M) |
| Gross Margin %(computed) | 100.00% | -102.26% | — | -515.59% | -155.32% |
| Operating Expenses | |||||
| R&D Expenses | $3.18M | $14.04M | $28.23M | $11.22M | $20.21M |
| G&A Expenses | $11.18M | $14.43M | $12.42M | $11.58M | $12.17M |
| Total Operating Expenses | $14.37M | $28.48M | $40.65M | $22.80M | $32.38M |
| Operating Income | ($6.36M) | ($21.53M) | ($40.24M) | ($20.98M) | ($24.47M) |
| Operating Margin %(computed) | -79.44% | -310.15% | — | — | -309.06% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.06M | $0.00M |
| Interest Expense | $0.01M | $0.01M | $0.07M | $0.00M | $2.10M |
| Income Before Tax | ($5.69M) | ($21.10M) | ($39.47M) | ($20.91M) | ($23.88M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($5.69M) | ($20.66M) | ($39.52M) | ($20.90M) | ($25.95M) |
| Net Margin %(computed) | -71.12% | -297.58% | — | — | -327.71% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.96 | $-7.36 | $-22.14 | $-38.37 | $-386.21 |
| Wtd Avg Shares | 5.91M | 2.81M | 1.78M | 0.54M | 0.07M |
| EBITDA | ($5.65M) | ($21.06M) | ($39.38M) | ($20.90M) | ($21.75M) |
| EBITDA Margin %(computed) | -70.55% | -303.37% | — | — | -274.76% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Fresh Tracks Therapeutics, Inc. data
About Fresh Tracks Therapeutics, Inc. (FRTX) Income Statement
Fresh Tracks Therapeutics, Inc. (FRTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, FRTX reported revenue of $0.01B, gross profit of $0.01B (gross margin 100.00%), and net income of ($0.01B) — a net profit margin of -71.12%.
Frequently asked questions
FRTX · 4 questionsFresh Tracks Therapeutics, Inc. (FRTX) reported revenue of $0.01B for 2023, up 15.3% year-over-year.
FRTX revenueFRTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09